You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Mendus Q2´24: The CADENCE trial has started
Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with Ilixadencel.
00:00 Start
00:14 What has happened during Q2
04:58 The CADENCE trial
08:04 Main milestones in CADENCE
09:36 Immune activation in AML patients - What have you learned?
12:19 New trial with Ilixadencel
15:16 Timeline for the trial
15:54 Building readiness in AML
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
GomSpace – Management Q&A
ExpreS2ion Biotech – A look back at 2024 with CEO
View all videos